Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial

Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00157-1/fulltext?dgcid=hubspot_update_feature_updatealerts_lanrhe&utm_campaign=update-lanrhe&utm_medium=email&_hsmi=269331371&_hsenc=p2ANqtz--Nm9Ne7b5_vKEdKAwxjUZUNku61c_laaXP3tu7H__s8SK0d9W-k8P1WjrRiBSf6eJpOCijjsjGVI6ck35xwoyHgEFeCw&utm_content=269313719&utm_source=hs_email